• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Open Heart . Coronary artery disease in patients hospitalised with Coronavirus disease 2019 (COVID-19) infection

tetano

Editor, Senior Moderator
Open Heart


. 2020 Nov;7(2):e001428.
doi: 10.1136/openhrt-2020-001428.
Coronary artery disease in patients hospitalised with Coronavirus disease 2019 (COVID-19) infection


Marco Loffi[SUP] #[/SUP][SUP] 1 [/SUP], Raffaele Piccolo[SUP] #[/SUP][SUP] 2 [/SUP], Valentina Regazzoni[SUP] 3 [/SUP], Giuseppe Di Tano[SUP] 3 [/SUP], Luigi Moschini[SUP] 3 [/SUP], Debora Robba[SUP] 3 [/SUP], Filippo Quinzani[SUP] 3 [/SUP], Giovanni Esposito[SUP] 4 [/SUP], Anna Franzone[SUP] 2 [/SUP], Gian Battista Danzi[SUP] 3 [/SUP]



Affiliations

Abstract

Objective: Among patients with Coronavirus disease 2019 (COVID-19), coronary artery disease (CAD) has been identified as a high-risk condition. We aimed to assess the clinical outcomes and mortality among patients with COVID-19 according to CAD status.
Methods: We retrospectively analysed data from patients with COVID-19 admitted to the Cremona Hospital (Lombardy region, Italy) between February and March 2020. The primary outcome was all-cause mortality. CAD was defined as a history of prior myocardial infarction (MI), prior percutaneous coronary intervention (PCI), prior coronary artery bypass grafting (CABG) or CAD that was being medically treated.
Results: Of 1252 consecutive patients with COVID-19, 124 (9.9%) had concomitant CAD. Patients with CAD were older and had a higher prevalence of comorbidities compared with those without CAD. Although patients with CAD had a higher risk of all-cause mortality than patients without CAD (HR 3.01, 95% CI 2.27 to 3.99), this difference was no longer significant in the adjusted model (HR 1.14, 95% CI 0.79 to 1.63). Results were consistent among patients with prior MI (adjusted HR (aHR) 0.87, 95% CI 0.54 to 1.41), prior PCI (aHR 1.10, 95% CI 0.75 to 1.62), prior CABG (aHR 0.91, 95% CI 0.45 to 1.82), or CAD medically treated (aHR 0.84, 95% CI 0.29 to 2.44). Multivariable analysis showed that age (aHR per 5 year increase 1.62, 95% CI 1.53 to 1.72) and female sex (aHR 0.63, 95% CI 0.49 to 0.82) were the only two independent correlates of mortality.
Conclusion: Patients with COVID-19 and CAD have an exceedingly higher risk of mortality, which is mainly attributable to the burden of comorbidities rather than to a direct effect of CAD per se.

Keywords: atherosclerosis; coronary artery disease; risk stratification.
 
Back
Top Bottom